Serious Adverse Events and Laboratory Monitoring Regimens for Outpatient Parenteral Antimicrobial Therapy With...

Area of Science:

• Infectious Diseases
• Clinical Pharmacy
• Pharmacovigilance

Background:

• Outpatient parenteral antimicrobial therapy (OPAT) requires careful monitoring for adverse events.
• The optimal frequency of laboratory monitoring for daptomycin-related adverse events in OPAT is not established.
• Daptomycin is a critical antibiotic for various infections managed in OPAT settings.

Purpose of the Study:

• To determine the incidence of adverse events related to daptomycin therapy in OPAT patients.
• To evaluate the effectiveness of current laboratory monitoring protocols for daptomycin OPAT.
• To inform guidelines on appropriate laboratory monitoring frequency for daptomycin in OPAT.

Main Methods:

• Retrospective analysis of laboratory test data from patients receiving daptomycin for OPAT.
• Calculation of the incidence of outpatient parenteral antimicrobial therapy-related adverse events (OPAT-AEs) per set of weekly laboratory tests.
• Assessment of adverse event rates in relation to monitoring frequency.

Main Results:

• A low incidence of 6.6 OPAT-AEs was identified per 1000 sets of weekly laboratory tests.
• The findings suggest that current weekly monitoring may exceed the necessary frequency for detecting daptomycin-related adverse events.
• No significant increase in adverse events was observed with less intensive monitoring intervals.

Conclusions:

• Less intensive laboratory monitoring may be a safe and reasonable approach for patients receiving daptomycin for OPAT.
• Current monitoring guidelines for daptomycin OPAT may be adjusted to reduce healthcare resource utilization.
• Further prospective studies are warranted to confirm these findings and establish definitive monitoring protocols.